Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Caicun Zhou(Tongji University), Jason Yang, Jiuwei Cui(Jilin University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Rumei Chen, Si Sun(Wuhan University), Jingzhang Li(Liuzhou General Hospital), Meili Sun(Jinan Central Hospital), Jianhua Chen(Xinjiang Medical University), You Lü(Sichuan University), Chunhong Hu(Central South University), Ping Sun(University of Electronic Science and Technology of China), Xueqin Chen(Ningbo No. 2 Hospital), Chunling Liu(Xinjiang Medical University), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Hao Wang(Stevens Institute of Technology), Kangsheng Gu(Anhui Medical University), Yiping Zhang(National Health and Family Planning Commission), Hui Zhao(Dalian Medical University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongqian Shu(Jiangsu Province Hospital), Ziping Wang(University of Science and Technology of China), Jiwei Liu(Mongolian University of Science and Technology), Xingya Li(Zhengzhou University), Wu Zhuang(Hunan University), Yan Yu(Binzhou Medical University), Jingru Wang(Sun Yat-sen University), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Rong Wu(China Medical University), Wenxiu Yao(Sichuan Cancer Hospital), Hong Shen(Central South University), Zhiyong Ma(Zhengzhou University), Mengmeng Qin(Tianjin University)
Cited by 34
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695